← Back to Search

iKinnect2.0 App for Suicide Risk in Youth

N/A
Waitlist Available
Led By Cindy Schaeffer, PhD
Research Sponsored by Evidence-Based Practice Institute, Seattle, WA
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
PARENT/GUARDIAN: 18 years or older
YOUTH: Age 15-21 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (time1), 1-4 weeks (time 2), 5-8 weeks (time 3), and 9-16 weeks (time 4)
Awards & highlights

Study Summary

This trial will test a new app, iKinnect2.0, for suicide prevention in 120 young adults aged 15-21 who have been involved in the juvenile justice system, compared to an existing app, Life360, plus an electronic suicide resources brochure.

Who is the study for?
This trial is for English-speaking youth aged 15-21 at high risk of suicide, with a history of self-harm or attempts, who use a smartphone with data and live with their primary caregiver. Caregivers must also participate, be fluent in English, and have a smartphone. Youth should be involved in juvenile justice services.Check my eligibility
What is being tested?
The study compares iKinnect2.0, an app designed to help prevent suicide among young people involved in the juvenile justice system, against Life360 (a control app) plus electronic resources on suicide prevention over a period of 16 weeks.See study design
What are the potential side effects?
There are no direct physical side effects mentioned for participating in this trial as it involves the use of mobile applications; however, discussing sensitive topics like suicidal behavior may cause emotional discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a parent or guardian aged 18 or older.
Select...
I am between 15 and 21 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (time1), 1-4 weeks (time 2), 5-8 weeks (time 3), and 9-16 weeks (time 4)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (time1), 1-4 weeks (time 2), 5-8 weeks (time 3), and 9-16 weeks (time 4) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Achenbach (Child/Adult) Behavior Checklist
Change in Center for Epidemiological Studies-Depression Scale (CES-D)
Change in Loeber Parenting Scale
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: iKinnect2.0Experimental Treatment1 Intervention
Parent-Youth dyads assigned to the iKinnect2.0 condition will be given access to the iKinnect2.0 app that has been developed for this study. Parent and youth will be asked to download the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial. The app is designed to be used several times throughout each day.
Group II: Attention-Control Placebo App & Supporting MaterialsPlacebo Group1 Intervention
Parent-Youth dyads assigned to the control condition will be asked to download the free Life360 app to their phone during the baseline assessment process and will also be given access to an online suicide resources brochure. Participants will be asked to use the control-condition app and associated materials as often as they would like throughout the duration of the 16 week trial.

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,782 Previous Clinical Trials
2,688,867 Total Patients Enrolled
University of MarylandOTHER
160 Previous Clinical Trials
302,043 Total Patients Enrolled
Evidence-Based Practice Institute, Seattle, WALead Sponsor
8 Previous Clinical Trials
29,537 Total Patients Enrolled

Media Library

iKinnect2.0 Clinical Trial Eligibility Overview. Trial Name: NCT04909203 — N/A
Suicide and Self-Harm Research Study Groups: Attention-Control Placebo App & Supporting Materials, iKinnect2.0
Suicide and Self-Harm Clinical Trial 2023: iKinnect2.0 Highlights & Side Effects. Trial Name: NCT04909203 — N/A
iKinnect2.0 2023 Treatment Timeline for Medical Study. Trial Name: NCT04909203 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there an open enrollment period for this research initiative?

"According to the records available on clinicaltrials.gov, this medical study is not open for recruitment at present. It was initially posted in February of 2023 and last updated in March 2022. However, there are currently 553 other investigations that are actively seeking patients' participation."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
iKinnect2.0 for Juvenile Justice Involved Youth at Risk for Suicide
2023. "iKinnect2.0 for Juvenile Justice Involved Youth at Risk for Suicide". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04909203.
~65 spots leftby Jul 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top